CytoSorbents CTSO is ready to offer its newest quarterly earnings report on Monday, 2025-03-31. Here is what buyers have to know earlier than the announcement.
Analysts estimate that CytoSorbents will report an earnings per share (EPS) of $-0.07.
Traders in CytoSorbents are eagerly awaiting the corporate’s announcement, hoping for information of surpassing estimates and constructive steering for the subsequent quarter.
It is price noting for brand spanking new buyers that inventory costs could be closely influenced by future projections moderately than simply previous efficiency.
Historic Earnings Efficiency
Within the earlier earnings launch, the corporate beat EPS by $0.02, resulting in a 18.05% drop within the share value the next buying and selling session.
Here is a have a look at CytoSorbents’s previous efficiency and the ensuing value change:
Quarter
Q3 2024
Q2 2024
Q1 2024
This fall 2023
EPS Estimate
-0.06
-0.09
-0.12
-0.14
EPS Precise
-0.04
-0.08
-0.12
-0.12
Worth Change %
-18.0%
8.0%
12.0%
-9.0%
CytoSorbents Share Worth Evaluation
Shares of CytoSorbents had been buying and selling at $1.0 as of March 27. Over the past 52-week interval, shares are up 9.36%. Provided that these returns are typically constructive, long-term shareholders are possible bullish going into this earnings launch.
Analyst Insights on CytoSorbents
Understanding market sentiments and expectations throughout the trade is essential for buyers. This evaluation delves into the newest insights on CytoSorbents.
Analysts have given CytoSorbents a complete of three scores, with the consensus score being Purchase. The typical one-year value goal is $10.0, indicating a possible 900.0% upside.
Peer Scores Comparability
The beneath comparability of the analyst scores and common 1-year value targets of Hyperfine, Fractyl Well being and electroCore, three distinguished gamers within the trade, provides insights for his or her relative efficiency expectations and market positioning.
Hyperfine acquired a Purchase consensus from analysts, with a mean 1-year value goal of $1.33, implying a possible 33.0% upside.
Analysts at present favor an Outperform trajectory for Fractyl Well being, with a mean 1-year value goal of $10.0, suggesting a possible 900.0% upside.
Analysts at present favor an Purchase trajectory for electroCore, with a mean 1-year value goal of $25.5, suggesting a possible 2450.0% upside.
Key Findings: Peer Evaluation Abstract
The peer evaluation abstract provides an in depth examination of key metrics for Hyperfine, Fractyl Well being and electroCore, offering useful insights into their respective standings throughout the trade and their market positions and comparative efficiency.
Firm
Consensus
Income Progress
Gross Revenue
Return on Fairness
CytoSorbents
Purchase
11.08%
$4.50M
-15.70%
Hyperfine
Purchase
-13.59%
$826K
-19.36%
Fractyl Well being
Outperform
-57.14%
$3K
-63.42%
electroCore
Purchase
35.73%
$6.05M
-37.98%
Key Takeaway:
CytoSorbents ranks on the high for Income Progress and Gross Revenue amongst its friends. Nonetheless, it ranks on the backside for Return on Fairness. Total, CytoSorbents reveals robust income development and gross revenue efficiency in comparison with its friends, however lags behind by way of return on fairness.
Delving into CytoSorbents’s Background
CytoSorbents Corp makes a speciality of treating life-threatening situations in intensive care and cardiac surgical procedure utilizing proprietary polymer adsorption know-how. Its flagship product, CytoSorb, is accredited within the EU as an extracorporeal cytokine absorber, aiming to cut back irritation and forestall a number of organ failure in essential sicknesses like sepsis and trauma. Income primarily comes from product gross sales in Germany, with extra revenue from grant companies in america. The corporate operates by Direct gross sales, Distributors/strategic companions, and Authorities segments. The corporate’s product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
Monetary Milestones: CytoSorbents’s Journey
Market Capitalization Evaluation: The corporate’s market capitalization is beneath the trade common, suggesting that it’s comparatively smaller in comparison with friends. This may very well be attributable to varied elements, together with perceived development potential or operational scale.
Constructive Income Development: Inspecting CytoSorbents’s financials over 3 months reveals a constructive narrative. The corporate achieved a noteworthy income development fee of 11.08% as of 30 September, 2024, showcasing a considerable enhance in top-line earnings. Compared to its trade friends, the corporate trails behind with a development fee decrease than the common amongst friends within the Well being Care sector.
Web Margin: CytoSorbents’s internet margin is spectacular, surpassing trade averages. With a internet margin of -27.1%, the corporate demonstrates robust profitability and efficient value administration.
Return on Fairness (ROE): The corporate’s ROE is beneath trade benchmarks, signaling potential difficulties in effectively utilizing fairness capital. With an ROE of -15.7%, the corporate might have to handle challenges in producing passable returns for shareholders.
Return on Property (ROA): The corporate’s ROA is a standout performer, exceeding trade averages. With a formidable ROA of -4.61%, the corporate showcases efficient utilization of property.
Debt Administration: With a excessive debt-to-equity ratio of two.06, CytoSorbents faces challenges in successfully managing its debt ranges, indicating potential monetary pressure.
To trace all earnings releases for CytoSorbents go to their earnings calendar on our website.
This text was generated by Benzinga’s automated content material engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
